TG Therapeutics vs Telix Pharmaceuticals
Telix Pharmaceuticals is the larger business, with $804m of revenue in fiscal 2025 against $616m for TG Therapeutics (1.3 times as much). TG Therapeutics grew faster (87.3% against 55.6%). TG Therapeutics kept more of each dollar of sales as profit: a net margin of 72.6% against -0.9%. TG Therapeutics carries less debt relative to equity (37.9% against 97.5%).
| Latest fiscal year | TG TherapeuticsTGTX, 2025 | Telix PharmaceuticalsTLX, 2025 |
|---|---|---|
| Revenue | $616m | $804m |
| Revenue growth | 87.3% | 55.6% |
| Net income | $447m | −$7.1m |
| Operating margin | 20.0% | 3.7% |
| Net margin | 72.6% | -0.9% |
| Return on equity | 102.8% | -1.9% |
| Free cash flow | −$25.0m | −$43.0m |
| Cash | $79.1m | $142m |
| Total debt | $246m | $405m |
| Debt to equity | 37.9% | 97.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $91.2m | — |
| Employees | 399 | — |
| Market value | $9.32bn | $3.05bn |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 0 buys, 2 sales | 3 buys, 0 sales |